Serum Tenascin-C Concentration in Patients With Acute Coronary Syndrome

Completed

• Conditions: Acute Coronary Syndrome

• Registration Number: NCT02767960
• Lead Sponsor: The First Affiliated Hospital of Dalian Medical University

Brief Summary

This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Detailed Description

It is found that Tenascin-C plays an important role in ventricular remodeling, heart failure, aortic dissection, rheumatic heart disease and other cardiovascular diseases, which may be a new marker for the diagnosis and prognosis prediction of these diseases. However, there is few relevant studies about the Tenascin-C concentration in patients with acute coronary syndrome.This study valuates the serum Tenascin-C concentration in patients with acute coronary syndrome.

Study Timeline

• Study Start: 2016-05
• Study First Submitted: 2016-05-03
• Study First Submitted QC: 2016-05-06
• Study First Posted: 2016-05-11
• Primary Completion: 2017-01
• Status Verified: 2017-07
• Study Completion: 2017-07
• Last Update Submitted: 2017-07-29
• Last Update Posted: 2017-08-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 183

Inclusion Criteria

.diagnosed as acute coronary syndrome,including STEMI,non-STEMI,and UAP.

• with left ventricular ejection fraction（LVEF）>=45%
• written informed consents are obtained
• admitted within 24 hours after chest pain attacked

Exclusion Criteria

• complicated with rheumatic heart disease, coronary arteritis, hypertrophic cardiomyopathy or dilated cardiomyopathy
• complicated with malignant tumor,the immune system diseases, blood system diseases, recently (within 2 weeks) taking glucocorticoid drugs, the use of immunosuppressive agents and cerebral infarction
• with acute or chronic infection, surgery or trauma in the last month
• secondary hypertension, severe liver dysfunction,severe renal insufficiency
• with abnormal thyroid function or allergy to iodine agent
• refusal to sign the informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Tenascin-C concentration	12 months	Serum Tenascin-C concentration in ng/ml

Secondary Outcome Measures

Name	Time	Method
Relationship between Tenascin-C and high sensitive C reaction protein (hs-CRP) concentration	12 months	With or without association between them
Relationship between Tenascin-C and Troponin-I (Tn-I) concentration	12 months	With or without association between them
MACEs during 12-month follow-up	12 months	All major adverse cardiac events( MACEs) including death, myocardial infarction, angina, heart failure are recorded.

Trial Locations

Locations (1)

The First Affiliated Hospital of Dalian Medical University; 🇨🇳 Dalian, Liaoning, China